The 14.2% discount to market and immediate dilution of $13.95 per share signal near-term selling pressure. Monitor for potential further equity raises given the company's pre-commercial status and broad discretion over proceeds. The underwriters' 30-day option for additional shares adds overhang. Watch for any clinical catalysts (darovasertib NDA filing in H2 2026) that could offset dilution concerns.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 10 $27.60entry
- T+1 · 5mo ago +4.49%α +2.79% · $28.84
- T+5 · 5mo ago +10.76%α +7.33% · $30.57
- T+20 · 4mo ago +35.07%α +31.45% · $37.28
- T+60 · 2mo ago +44.82%α +38.24% · $39.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, priced at $27.00 per share (and $26.9999 per pre-funded warrant). The offering represents roughly 6.3% dilution to existing shareholders based on shares outstanding as of March 31, 2026, and was priced at a 14.2% discount to the last closing price of $31.48. Proceeds will fund continued clinical development and potential commercialization of darovasertib for uveal melanoma, pipeline advancement, and general corporate purposes.
Key Facts
- Offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares at $27.00 per share/$26.9999 per warrant
- Net proceeds of approximately $281.3 million ($323.6 million if underwriters' option exercised in full)
- Priced at a 14.2% discount to the $31.48 closing price on June 8, 2026
- Immediate dilution of $13.95 per share to new investors; as-adjusted net tangible book value increases from $10.67 to $13.05 per share
- Underwriters have a 30-day option to purchase up to 1,666,669 additional shares
- Proceeds to fund darovasertib development, pipeline advancement, and general corporate purposes
- Lock-up agreements with directors and executive officers for 60 days post-offering
Financial Impact
~$300M gross offering; ~$282M net proceeds; ~6.3% dilution to existing shareholders based on 87.9M shares outstanding pre-offering
Risk Factors
- Immediate and substantial dilution to existing shareholders ($13.95 per share)
- Potential for further equity offerings given pre-revenue status and broad capital needs
- Underwriters' option for additional shares creates near-term overhang
- No guarantee that proceeds will enhance shareholder value given management's broad discretion
- Stock price volatility common in biotechnology sector
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-264032 |
| Document: d160204dexfilingfees.htm | 0001193125-26-264032 |
| Document: 0001193125-26-264032-index-headers.html | 0001193125-26-264032 |
| Document: 0001193125-26-264032-index.html | 0001193125-26-264032 |
| Document: 0001193125-26-264032.txt | 0001193125-26-264032 |
Track record
13 reports on IDYA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Viewing Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers